AstraZeneca’s hopes of positioning its PD-L1 inhibitor Imfinzi as a post-surgery therapy for people with earlier-stage lung cancer have taken a knock, although it performed well in a bladder ...

AstraZeneca's PD-L1 inhibitor Imfinzi has become the immunotherapy to be approved in the US for limited-stage small cell lung cancer (LS-SCLC), a particularly challenging form of the disease.

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

Durvalumab (brand name Imfinzi) is a treatment for non small cell lung cancer (NSCLC) but is also being trialled in other cancers. James Catto, professor of urology at the University of Sheffield ...

Immunotherapy drug durvalumab, sold under the brand name Imfinzi, could help reduce the risk of bladder cancer progressing or returning to patients, according to a new study. Patients were given ...

Imfinzi is a key revenue driver for AZN’s oncology portfolio, having generated sales worth $3.46 billion in the first nine months of 2024, up 22% year over year at constant exchange rates ...